Humacyte(HUMA) ZACKS·2025-05-13 13:45Company Performance - Humacyte, Inc. reported a quarterly loss of 0.19, and an improvement from a loss of 0.52 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 2.45%, compared to zero revenues a year ago [2] - Humacyte's shares have declined approximately 73.9% since the beginning of the year, contrasting with the S&P 500's decline of only 0.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -1.05 million, and for the current fiscal year, it is -9.66 million [7] - The estimate revisions trend for Humacyte is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expectations of outperforming the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Humacyte belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]